Pfizer company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A new market commentary framed Pfizer’s stock decision around the possibility of a tougher operating period ahead, while noting that investors will likely weigh valuation against near-term uncertainties.
THE APEX TIMES
THE APEX TIMES
The agreement covers multiple federal lawsuits involving its Depo-Provera contraceptive and claims of an increased risk of intracranial meningioma, according to a report.
THE APEX TIMES
Pfizer’s shares have trailed the S&P 500 over the past year, according to a market snapshot cited by Yahoo Finance, even as Wall Street sentiment toward the company remains only moderately cautious.
THE APEX TIMES
A new market report frames Pfizer’s near-term oncology momentum around Padcev, while pointing to PF-08634404 and potential label expansion efforts as catalysts the company expects to matter later.
THE APEX TIMES
Both Pfizer and Starbucks raised their outlooks this summer, but the difference in how aggressive each company’s recovery narrative is can shape investor expectations about durability, cost control, and the timing of cash flow improvements.
THE APEX TIMES
The companies announced U.S. regulatory approval for an additional version of their jointly developed mRNA COVID-19 vaccine, underscoring the continuing cycle of variant updates.
THE APEX TIMES
The company’s newly updated shot, adapted from its XFG program, is being rolled out with deliveries starting immediately to pharmacies and clinics.
THE APEX TIMES
BioNTech’s colorectal cancer vaccine trial collapsed in Phase 2, a setback that pressured peer stocks including Moderna and weighed on investors’ expectations for mRNA oncology programs. Pfizer, which also has a stake in mRNA vaccine development through collaborations, was reported to hold roughly flat on the day.
THE APEX TIMES
A newly released industry report projects the cytotoxic drugs market rising from $16.21 billion in 2026 to $21.06 billion by 2031, citing improving access to cancer screening and treatment, including for oral therapies and newer drug formats.
